On November 10, 2021 Sysmex reported that (Press release, Sysmex, NOV 10, 2021, View Source [SID1234595214])
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
1. Results for the First Six Months of the Fiscal Year Ending March 31, 2022
(1) Operating results
(2) Financial condition
2. Dividend
3. Financial Forecast for the Year Ending March 31, 20224.
Other Information
(1) Changes in significant consolidated subsidiaries (which resulted in changes in scope of consolidation):
No (2) Changes in accounting policies and accounting estimates
1) Changes in accounting policies required by IFRS:
No 2) Other changes in accounting policies:
No 3) Changes in accounting estimates:
No (3) Number of outstanding stock (common stock)
1) Number of outstanding stock at the end of each fiscal period (including treasury stock): 209,485,632 shares as of Sep. 30, 2021; 209,443,232 shares as of Mar. 31, 2021
2) Number of treasury stock at the end of each fiscal period: 447,055 shares as of Sep. 30, 2021; 446,876 shares as of Mar. 31, 2021
3) Average number of outstanding stock for each period (cumulative): 209,014,581 shares for the six months ended Sep. 30, 2021 208,859,643 shares for the six months ended Sep. 30, 20201.
Qualitative information on quarterly financial results
1) Operating performance analysis Future-related information contained in the text below is based on the judgement as of the end of the fiscal period under review. During the first six months of the fiscal year ending March 31, 2022, the Japanese economy was affected by the COVID-19 pandemic. Despite progress with rolling out vaccines, social activity and personal consumption remained sluggish, due to reissuing the state of emergency and the priority preventative measures. Overseas, economic deregulation led to a gradual economic recovery, albeit with variations among countries and regions. Even so, the outlook remains uncertain due to the gradual shrinking of fiscal and monetary policies and the impact of the global shortage of semiconductors. On the healthcare front, we are seeing major changes in the healthcare environment due to the COVID-19 pandemic, as well as an aging society and increasingly diverse health and medical needs.
In Japan, expectations are mounting for new medical services to address the "new normal," such as resolving the pressure on medical systems due to a rise in the number of infections, stable supplies of necessary supplies and a response to digitalization in the medical field. Looking overseas, aging populations in developed countries are driving demand for the moderation of medical systems. In emerging markets, healthcare demand is increasing, and demand is rising for higher levels of healthcare quality, service enhancements and preventive medicine. As a result, we are seeing rapid advances in the application of artificial intelligence, big data analysis and other leading-edge technologies, which are expected to provide further opportunities for growth. Against this backdrop, Sysmex continued to expand its product portfolio in the hematology field. We launched a next-generation flagship model, XR-Series Automated Hematology Analyzer, and a compact three-part differential model, the XQ-Series Automated Hematology Analyzer in Japan. We will continue with a global sales rollout after receiving regulatory approval in individual countries.
We aim to contribute optimization of laboratory operations according to regional characteristics and facilities’ needs. In the life science field, we formed a strategic alliance related to joint development and global business with QIAGEN N.V., which has extensive experience in the development of companion diagnostics*1 in the field of oncology. By leveraging QIAGEN’s experience in developing companion diagnostics, Sysmex expects to strengthen its global relationships with pharmaceutical companies. We will work toward the early development and clinical implementation of companion diagnostics. "Genetic diagnosis and counseling for inherited retinal dystrophy (IRD)*
2 using a genetic testing system (tentatively named the IRD Panel Testing System), which Sysmex and the Kobe City Eye Hospital have been developing jointly, has received Advanced Medical Care B*3 approval. Going forward, we will commence this testing at the Kobe City Eye Hospital. In addition, we will increase the number of cooperating facilities for advance medical care that can perform this test, in the aim of increasing opportunities for patients to receive medical care. As the global general distributor, Sysmex continued to market hinotori to medical institutions in Japan. (The hinotori Surgical Robot System is the first made-in-Japan robotic-assisted surgery system.) We are working with Medicaroid Corporation, a joint venture between Sysmex and Kawasaki Heavy Industry, Ltd., to obtain regulatory approval overseas, and we will begin introducing the system in overseas markets, as well.
*1 Companion diagnostics: Testing to predict the efficacy or risk of side effects of specific drugs before prescription. *2 Inherited retinal dystrophy (IRD): IRD is an inherited progressive disease thought to be caused by genetic mutations. The main symptoms are night blindness, narrowing of the visual field, and loss of vision, which can lead to blindness in some cases. Several diseases with similar symptoms are collectively referred to as inherited retinal dystrophy.
*3 Advanced medical care B: Advanced medical care is new experimental medical technology whose effectiveness and safety have not yet been evaluated, and which has been designated by the Ministry of Health, Labor and Welfare as a medical technology to be evaluated for effectiveness and safety in order to determine whether it should be covered by insurance in the future. Within this category, Advanced medical care B may be conducted only at medical institutions that meet the facility criteria set for each medical technology.